What Redberry does

Redberry is a French biotechnology company, founded in 2018 and headquartered in Illkirch-Graffenstaden (Alsace, near Strasbourg), that develops and commercializes automated rapid microbiology testing instruments built on Solid-Phase Cytometry (SPC). The company's core platform, Red One™, integrates membrane filtration, proprietary fluorescein-based viability staining, high-resolution CMOS imaging, and AI-based image analysis into a single closed aseptic workflow that detects and counts single viable microbial cells based on esterase activity. Time-resolved fluorescence monitoring (staining kinetics) distinguishes viable cells from inert or autofluorescent particles, with the company claiming elimination of more than 99% of non-specific signals. The platform delivers results in 10 minutes for rapid screening, 4 hours for bioburden enumeration, and 4 days for sterility testing, compressing traditional compendial timelines of 5 days (bioburden) and 14 days (sterility). Red One is validated under European Pharmacopeia 2.6.1 and 2.6.27, aligned with PE 5.1.6 and PDA TR.33, and compliant with 21 CFR Part 11. Additional products include the ColiMinder® CMI-02 continuous water quality monitor and a forthcoming Matipi™ line; the ColiRed™ application enables same-day E. coli enumeration in drinking water.

Redberry monetizes the platform through direct enterprise sales of instruments and recurring single-use cap consumables (0.4μm track-etched PET membranes), supplemented by Primary Validation Packages and Performance Qualification support services. The go-to-market motion is enterprise field sales — with dedicated contacts in France (HQ) and the United States (Dina Laoui) — augmented by heavy participation in pharmaceutical and water industry conferences (ECA, PDA, Pharmalab, Pharmig, JIE, SFM) and joint scientific presentations with named customers including Sanofi, Procter & Gamble, Eurofins, GE HealthCare, Veolia, and Eau de Paris. Primary customer segments are pharmaceutical manufacturers (especially ATMP, cell therapy, and radiopharmaceutical producers constrained by short product shelf life), personal care / FMCG companies, and water utilities and municipalities; the company has cited selective lysis protocols (>99.99% mammalian cell reduction) specifically for ATMP applications. Pricing is not publicly disclosed and is quote-based, consistent with multi-year enterprise contracts.

In November 2025, Lonza, a Swiss contract development and manufacturing organization, signed an agreement to acquire Redberry SAS, intending to integrate the Red One rapid sterility testing platform into Lonza's quality control ecosystem to serve pharmaceutical customers requiring fast, scalable QC for short-shelf-life products. The transaction was pending completion at the time of the most recent reporting. The company has raised approximately €1 million in disclosed funding (October 2022) and has received non-dilutive FEDER support and multiple innovation awards from French and European institutions (ADEME, French Ministry of Research, Janus Design Institute, Tech Tour, Eau de Paris, The Water Council).

Name

Redberry

Legal name

REDBERRY SAS

Website

https://redberry.net

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Redberry is a French biotechnology company that builds automated Solid-Phase Cytometry instruments (Red One™) for rapid microbiology quality control, serving pharmaceutical manufacturers, cell and gene therapy producers, water utilities, and personal care companies with sterility, bioburden, and screening results delivered in hours or days rather than weeks.

Ownership category

akta.pro rank

Product category

Rapid Microbiology Testing Equipment

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

akta.pro secondary industries

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD)

Keywords

• Rapid microbiology testing
• Solid-phase cytometry
• Microbial quality control
• Bioburden analysis
• Sterility testing systems

Headquarters

HQ city

Illkirch-graffenstaden

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Red One Platform Sales and Service: Sale of the Red One automated solid-phase cytometry platform and associated consumables (single-use caps) to pharmaceutical, personal care, and water testing laboratories for rapid microbiology quality control testing.
2. Microbiology Testing Solutions — Instruments and Consumables: Revenue generated from instrument sales and recurring consumable revenue (single-use caps/membranes) for quality control microbiology testing in pharmaceutical, personal care, and water sectors.
3. Scientific Consulting and Validation Services: Redberry offers Primary Validation Package (PE 5.1.6 and PDA TR.33) and support for Validation for Intended Use (PQ) — suggesting professional services revenue from validation support engagements.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Redberry develops and commercializes the Red One™ automated solid-phase cytometry platform, which performs rapid microbial detection and enumeration in pharmaceutical, water, and personal care samples. The company supplements hardware sales with proprietary consumables, applications (including E. coli detection via ColiRed™), and scientific consulting and validation services (USP <61>, <62>, <1116>, PE 5.1.6, PDA TR.33) tailored to industrial quality-control laboratories.

Product overview

Redberry is a rapid microbiology testing company offering solutions based on Solid-Phase Cytometry technology through its Red One™ platform—the core automated system that integrates filtration, staining, and analysis in a single workflow. The platform supports three main applications: Direct Viable Count (10-minute rapid screening), Bioburden testing (4-hour quantitative analysis), and Sterility testing (4-day compendial method). Additional products include Matipi™ (forthcoming) and ColiMinder® CMI-02 (water quality monitoring device). The technology targets pharmaceutical quality control, personal care products, and water testing applications, with validation packages aligned to European and US Pharmacopeia standards.

Differentiator

Problem solved

Functional benefit

Brands

• Red One™: Automated solid-phase cytometry platform for instantaneous microbial detection in pharmaceuticals, waters, and personal care products. Delivers results in 10 minutes for rapid screening, 4 hours for bioburden, and 4 days for sterility testing.
• Matipi™
• ColiMinder®
• ColiRed™

Products and services

• Red One™ Platform Fully automated solid-phase cytometry instrument that performs rapid microbial detection and enumeration in pharmaceutical, water, and personal-care samples, intended for industrial quality-control microbiology laboratories seeking same-day results in place of 3–7 day culture-based methods.
• ColiMinder® CMI-02 Continuous online monitoring instrument delivering early-warning detection of total coliform bacteria in water within approximately 3 hours, intended for drinking-water utilities and environmental testing laboratories.
• Primary Validation Package (USP <61>, <62>, <1116>, PE 5.1.6, PDA TR.33) Consulting and validation services that map the Red One workflow to pharmacopeial microbiological methods (USP <61>, <62>, <1116>, PE 5.1.6, PDA TR.33), intended for pharmaceutical QC laboratories that require documented method compliance.

Quantifiable outcome

• Sterility testing time reduced from 14 days (traditional compendial) to 4 days (96 hours) using Red One platform
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Partnerships

Two partnerships are on record, tiered core and minor.

• LonzacoreStrategic or Co-development Partner · 1 November 2025In November 2025, Lonza (contract development and manufacturing organization) signed an agreement to acquire Redberry SAS. The acquisition integrates Redberry's Red One rapid sterility testing platform into Lonza's quality control ecosystem, enabling 4-day sterility results vs. traditional 14-day compendial methods. The deal enhances Lonza's capabilities for customers requiring fast, scalable quality control solutions for products with short shelf life, including cell therapies and radiopharmaceuticals.
• Aérial (French environmental research organization)minorStrategic or Co-development PartnerJoint presentation at AFC 2021 on Rapid Flora enumeration in drinking waters. Collaboration on applying Red One technology to drinking water quality testing.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• MilliporeSigma (Merck KGaA): Life science tools giant offering microbiology testing consumables, filtration membranes, and EZ Product families for bioburden and sterility testing in pharma QC — adjacent competitor leveraging scale and installed base.
• Charles River Laboratories: Major CRO and CDMO with extensive endotoxin and rapid microbiology testing services (Endosafe, Accugenix) — serves overlapping pharma QC customers and represents a potential channel partnership or competitor.
• Becton Dickinson (BD): Diversified life sciences company with significant microbiology, flow cytometry, and lab automation offerings (BD FACSChorus, BD MAX) serving pharma QC and clinical diagnostics — broader portfolio but overlapping applications.
• Beckman Coulter (Danaher): Major flow cytometry and laboratory automation vendor whose CytoFLEX and related platforms overlap with Redberry's cytometry/imaging approach in life science and clinical applications.
• bioMérieux: Global leader in industrial and clinical microbiology, offering a broad portfolio of rapid and traditional microbiology testing solutions including BACT/ALERT for sterility testing — a broad incumbent serving the same pharma QC customers Redberry targets.
• Mettler-Toledo: Precision laboratory instruments manufacturer with microbiology-relevant products (pH, conductivity, density measurements) for QC labs — broader lab equipment incumbent serving similar pharma QC procurement channels.
• Sartorius: Bioprocessing and lab consumables supplier with microbiology testing products serving pharmaceutical manufacturers — broader bioprocess focus but overlapping pharma QC customer base.

Direct peers

• Rapid Micro Biosystems: US-based developer of the Growth Direct platform for automated, rapid bioburden and sterility testing in pharmaceutical QC — the closest direct competitor to Redberry's Red One, addressing the same applications with comparable time-to-result benefits.
• Celsis International (Lonza): Lonza-owned ATP-bioluminescence rapid microbiology platform for sterility and bioburden screening in pharma and personal care — directly competes with Red One on rapid screening and is now part of Redberry's acquirer, creating both overlap and integration dynamics.

Emerging players

• Eurofins Scientific: Global testing services network with pharmaceutical microbiology capabilities (Eurofins BioPharma Product Testing) — a documented Redberry collaboration partner that also competes in offering rapid microbiology services to pharma clients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@redberrysas829
• LinkedInlinkedin.com/company/redberry-sas

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redberry